Candidemia in Cancer Patients: A Prospective, Multicenter Surveillance Study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
In a surveillance study of candidemia in cancer patients that was conducted by the European Organization for Research and Treatment of Cancer, 249 episodes were noted; Candida albicans was isolated in 70% (63) of the 90 cases involving patients with solid tumors (tumor patients) and in 36% (58) of the 159 involving those with hematologic disease (hematology patients). Neutropenia in tumor patients and acute leukemia and antifungal prophylaxis in hematology patients were significantly associated with non-albicans candidemia in a multivariate analysis. Overall 30-day mortality was 39% (97 of 249). In a univariate analysis, Candida glabrata was associated with the highest mortality rate (odds ratio, 2.66). Two multivariate analyses showed that mortality was associated with older age and severity of the underlying disease. Among hematology patients, additional factors associated with mortality were allogeneic bone marrow transplantation, septic shock, and lack of antifungal prophylaxis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies also showed a significant association between receipt of antifungal prophylaxis as well as acute leukemia and a higher incidence of candidemia caused by Candida species other than C. albicans (41).”
In the citing paper
“In cancer patients, Viscoli et al. [18] also suggested that C. glabrata was associated with a higher mortality rate.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [18]
In the citing paper
“Other North American and European investigators confirmed these observations in larger hospital settings [10, 11, 13, 20, 22, 25, 26].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [11]
In the citing paper
“Candidemia due to C. parapsilosis has increased in frequency in pediatric populations and appears to be associated with a lower mortality rate than is candidemia due to other species of Candida [110-113].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [113]
In the citing paper
“Candidemia due to C. glabrata may be associated with increased mortality in patients with cancer [113].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [113]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174 · cited 1×
“However, this phenomenon has not been confirmed in large prospective studies [26-29].”
ResultSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 1×
“glabrata) in patients receiving fluconazole [23-25].”
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877 · cited 1×
“glabrata) in patients receiving fluconazole [23-25].”
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758 · cited 1×
“given about the patients' predisposing conditions [15].”
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · cited 2×
“glabrata [3, 4, 1522].”
Background
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“The most frequently implicated risk factors include the use of broad-spectrum antibacterial agents, use of central venous catheters, receipt of parenteral nutrition, receipt of renal replacement therapy by patients in ICUs, neutropenia, use of implantable prosthetic devices, and receipt of immunosuppressive agents (in…”
BackgroundPosaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
“The clinician must remember that yeast and fungal infections remain the primary cause of infection-associated death among patients with neutropenia or patients who undergo blood or bone marrow transplantation [200, 201].”
BackgroundGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
“increased mortality in patients with cancer [113].”
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“7%); this finding is consistent with the results of prior studies [20, 30, 43].”
Result(2006) · PubMed · Cited by 906
Self-citationEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Pappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845
“In a recent retrospective study of patients with cancer, Viscoli et al. [ 21 ] suggested significantly higher mortality associated with C. glabrata fungemia and a trend toward poorer outcomes associated with C. tropicalis fungemia, compared with mortality and outcomes associated with fungemia due to other Candida spec…”
ResultNon-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
Self-citationThe biology and chemistry of antifungal agents: A review
Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.045 · Cited by 664
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
“Age (yr) 1 43 (8) 29 (5) 8 (3) 2 (1) 18 (12) 72 (7) 1–19 24 (5) 25 (4) 1 ( 1) 7 (5) 5 (3) 49 (4) 20–44 88 (17) 113 (18) 42 (15) 28 (20) 26 (17) 201 (18) 45–64 129 (25) 178 (28) 82 (30) 42 (30) 41 (27) 307 (27) 65 232 (45) 281 (45) 142 (52) 62 (44) 63 (41) 514 (45)”
InfluentialOdabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ketchum, P. A., Finkelman, M. A., Rex, J. H., & Ostrosky-Zeichner, L. (2004) · Clinical Infectious Diseases · doi:10.1086/421944 · Cited by 642
Epidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
“glabrata accounts for approximately 16% of Candida fungemia worldwide (277) and occurs predominantly in patients with solid tumors and lymphoma (371) or in HSCT recipients (383, 384).”
BackgroundAlmirante, B., Rodríguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1829-1835.2005 · Cited by 566
“Malignancy 123 (36) 61 (35) 6 (20) 18 (58) 9 (75) 21 (27) Immunosuppressive therapy 130 (39) 64 (37) 6 (21) 16 (53) 9 (75) 29 (38) Neutropenia 38 (11) 10 (6) 0 8 (26) 8 (67) 9 (12) Renal failure 117 (34) 72 (41) 11 (38) 11 (36) 3 (25) 16 (21) Transplant patient 26 (8) 3 (2) 0 5 (15) 2 (17) 12 (15) HIV infection 15 (4)…”
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Self-citationTortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509
“As already reported [ 11 ], non-albicans Candida spp.”
BackgroundResultInfluentialEpidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478
“Other North American and European investigators confirmed these observations in larger hospital settings [10, 11, 13, 20, 22, 25, 26].”
BackgroundResultHistory of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
“Unfortunately, the attributable mortality rate of (systemic) fungal infections remains high [8,9].”
BackgroundGirmenia, C., Pagano, L., Martino, B., D'Antonio, D., Fanci, R., Specchia, G., Melillo, L., Buelli, M., Pizzarelli, G., Venditti, M., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1818-1828.2005 · Cited by 397
Self-citationEpidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
The direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Invasive candidiasis as a cause of sepsis in the critically ill patient
Delaloye, J., & Calandra, T. (2014) · Virulence · doi:10.4161/viru.26187 · Cited by 372
Invasive Saccharomyces Infection: A Comprehensive Review
Enache-Angoulvant, A., & Hennequin, C. (2005) · Clinical Infectious Diseases · doi:10.1086/497832 · Cited by 369
“Despite this spectrum of susceptibility, a favorable outcome was observed in 63% of cases revealed in our literature search, which is a slightly higher percentage than that reported for cases of invasive candidiasis [87].”
ResultThe changing face of epidemiology of invasive fungal disease in Europe
Lass‐Flörl, C. (2009) · Mycoses · doi:10.1111/j.1439-0507.2009.01691.x · Cited by 369
Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
“In addition, they have been associated with reduced survival in cancer patients with recent azole administration (17, 38, 45).”
BackgroundCandidaemia in Europe: epidemiology and resistance
TORTORANO, A., KIBBLER, C., PEMAN, J., BERNHARDT, H., KLINGSPOR, L., & GRILLOT, R. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.01.002 · Cited by 352
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
“Candida diseases played a pivotal role in the past in patients with malignancies [1–3].”
BackgroundSelf-citationDadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., & Dhama, K. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.028 · Cited by 332
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
“All of these factors have set the stage for a significant increase of invasive fungal infections caused by Candida spp.(3,7,13) Today, Candida spp.”
BackgroundAntifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310
Leaw, S. N., Chang, H. C., Sun, H. F., Barton, R., Bouchara, J.-P., & Chang, T. C. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.693-699.2006 · Cited by 308
Development of Candida-associated denture stomatitis: new insights
Pereira-Cenci, T., Del Bel Cury, A. A., Crielaard, W., & Ten Cate, J. M. (2008) · Journal of Applied Oral Science · doi:10.1590/s1678-77572008000200002 · Cited by 306
Uncommon opportunistic fungi: new nosocomial threats
Groll, A. H., & Walsh, T. J. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00005.x · Cited by 305
Castagnola, E., Fontana, V., Caviglia, I., Caruso, S., Faraci, M., Fioredda, F., Garre, M. L., Moroni, C., Conte, M., Losurdo, G., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522533 · Cited by 292
Self-citationEpidemiology of opportunistic fungal infections in Latin America
Nucci, M., Queiroz‐Telles, F., Tobón, A. M., Restrepo, A., & Colombo, A. L. (2010) · Clinical Infectious Diseases · doi:10.1086/655683 · Cited by 280
Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Töpelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.658-666.2006 · Cited by 273
“Responder (complete partial) 5 (56) 6 (50) 1 (17) 1 (10) 3 (50) 4 (40) 9 (43) 11 (34) Complete 0 0 0 0 2 (33) 3 (30) 2 (10) 3 (9) Partial 5 (56) 6 (50) 1 (17) 1 (10) 1 (17) 1 (10) 7 (33) 8 (25) Failure 4 (44) 6 (50) 5 (83) 9 (90) 3 (50) 6 (60) 12 (57) 21 (66) Stable disease 1 (11) 1 (8) 1 (17) 1 (10) 1 (17) 1 (10) 3 (…”
BackgroundPfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269
Glasmacher, A., Prentice, A., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegovic, B., & Schmidt-Wolf, I. G. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.052 · Cited by 264
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
“glabrata) have been identified in most studies [83, 174, 183].”
BackgroundKlotz, S. A., Chasin, B. S., Powell, B., Gaur, N. K., & Lipke, P. N. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.07.001 · Cited by 253
Viudes, A., Pemán, J., Cantón, E., Úbeda, P., López-Ribot, J., & Gobernado, M. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0822-1 · Cited by 250
“Confirming the data presented in previous reviews, bloodstream infections caused by Candida krusei and Candida glabrata carry the highest mortality rates [31, 37 ].”
BackgroundResultFungi of the Murine Gut: Episodic Variation and Proliferation during Antibiotic Treatment
Dollive, S., Chen, Y.-Y., Grunberg, S., Bittinger, K., Hoffmann, C., Vandivier, L., Cuff, C., Lewis, J. D., Wu, G. D., & Bushman, F. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071806 · Cited by 239
Vermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
“In C. glabrata candidaemia, mortality rates of 38–53% have been reported (Viscoli et al., 1999; Safdar andArmstrong, 2002; Klingspor et al., 2004).”
BackgroundAdvances and challenges in management of invasive mycoses
Patterson, T. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67381-3 · Cited by 230
Bassetti, M., Merelli, M., Righi, E., Diaz-Martin, A., Rosello, E. M., Luzzati, R., Parra, A., Trecarichi, E. M., Sanguinetti, M., Posteraro, B., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01998-13 · Cited by 228
Pappas, P. G. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.004 · Cited by 227
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D., Chawla, V., Young, J., & Hadley, S. (2008) · Clinical Infectious Diseases · doi:10.1086/529435 · Cited by 223
“tions, such as those with hematologic malignancies [20, 21],”
BackgroundAzie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222
“Mortality in patients with candidemia has ranged between 30% and 81% in previous reports (Anaissie et al., 1998; Chen et al., 2006; Colombo et al., 2006; Gudlaugsson et al., 2003; Horn et al., 2009b; Morgan et al., 2005; Nieto-Rodriguez et al., 1996; Nolla-Salas et al., 1997; Pagano et al., 2006; Poikonen et al., 2003…”
Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling
Weindl, G., Naglik, J. R., Kaesler, S., Biedermann, T., Hube, B., Korting, H. C., & Schaller, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28115 · Cited by 217
“Candida albicans is a ubiquitous commensal organism and the most common fungal pathogen of humans and accounts for more than 50% of all fungal systemic infections (7, 8).”
BackgroundBassetti, M., Taramasso, L., Nicco, E., Molinari, M. P., Mussap, M., & Viscoli, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024198 · Cited by 216
“These data are different with those reported in other similar studies were the highest mortality has been found in ICU or tumour and haematology patients [37,38].”
ResultSelf-citationJeu, L., Piacenti, F. J., Lyakhovetskiy, A. G., & Fung, H. B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80126-1 · Cited by 213
van Asbeck, E. C., Clemons, K. V., & Stevens, D. A. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903213393 · Cited by 210
“C. parapsilosis causes 17–50% of fungemia in children (Abi-Said et al. 1997; Krcmery & Barnes 2002; Krcmery et al. 1999; Viscoli et al. 1999; Wingard 1995).”
BackgroundBodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01130-5 · Cited by 209
Lockhart, S. R., Messer, S. A., Pfaller, M. A., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00803-08 · Cited by 206
Agarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., & Clark, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306291200 · Cited by 204
Epidemiology and treatment approaches in management of invasive fungal infections
Ito, J. I., Kriengkauykiat, Dadwal, S., & Kriengkauykiat (2011) · Clinical Epidemiology · doi:10.2147/clep.s12502 · Cited by 203
Central venous access in oncology: ESMO Clinical Practice Guidelines
Sousa, B., Furlanetto, J., Hutka, M., Gouveia, P., Wuerstlein, R., Mariz, J. M., Pinto, D., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv296 · Cited by 194
“Most cases are related to Candida albicans [88], but there is a tendency for an increase in non-albicans as well as resistance to azoles [57, 84].”
BackgroundRisk Factors forCandida tropicalisFungemia in Patients with Cancer
Kontoyiannis, D. P., Vaziri, I., Hanna, H. A., Boktour, M. R., Thornby, J. I., Hachem, R. Y., Bodey, G. P., & RAAD, I. I. (2001) · Clinical Infectious Diseases · doi:10.1086/323812 · Cited by 192
Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades
Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R., & Fox, A. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5709-5717.2003 · Cited by 190
“glabrata infections is noteworthy because of its decreased susceptibility to fluconazole (30, 31) and the high crude mortality rate of bloodstream infection (13, 43) In spite of its increased prominence, little is known of the population structure, epidemiology, and basic biology of C.”
BackgroundIncreasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., & Gottfredsson, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3489-3492.2002 · Cited by 188
“In recent years, some studies have reported an increase of candidemia due to Candida non-albicans species, with the threat of increased mortality and antifungal drug resistance (1, 10, 16, 21).”
BackgroundSandven, P. (2000) · PubMed · Cited by 185
Candida glabrata Fungemia: Experience in a Tertiary Care Center
Malani, A., Hmoud, J., Chiu, L., Carver, P. L., Bielaczyc, A., & Kauffman, C. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432939 · Cited by 184
“ulation studied [4, 6, 7, 10], and use of fluconazole [4,”
BackgroundVediyappan, G., Rossignol, T., & d'Enfert, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01638-09 · Cited by 183
Nosocomial Candidemia in Non-Neutropenic Patients at an Italian Tertiary Care Hospital
Luzzati, R., Amalfitano, G., Lazzarini, L., Soldani, F., Bellino, S., Solbiati, M., Danzi, M. C., Vento, S., Todeschini, G., Vivenza, C., et al. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000325 · Cited by 179
“in hematologic patients but not in solid tumor patients [ 14 ], supporting the hypothesis of the role of the degree of immunosuppression and the prolonged use of antifungal agents.”
BackgroundDiagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 178
“Thus, not only would fewer patients have received suboptimal treatment, but these cases might also have been less grave (3, 6, 20, 23, 38, 54, 55).”
BackgroundCandidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.
Playford, E. G., Marriott, D. J. E., Nguyen, Q. A., Chen, W., Ellis, D., Slavin, M. A., & Sorrell, T. C. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181760f42 · Cited by 175
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., López, J. D. S., Pitart, C., & Mensa, J. (2011) · Journal of Hospital Infection · doi:10.1016/j.jhin.2010.09.026 · Cited by 175
Guery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1338-7 · Cited by 173
“[18] also suggested that C.”
Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment
Vento, S., & Cainelli, F. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01218-x · Cited by 170
Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species
Cheng, M., Yang, Y.-L., Yao, T., Lin, C., Liu, J.-S., Tang, R.-B., Yu, K., Fan, Y.-H., Hsieh, K., Ho, M., et al. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-22 · Cited by 169
“In recent years, Candida species associated with candidemia have shifted from Candida albicans to non-albicans Candida species (NAC) [6].”
Pathogenicity and drug resistance in Candida albicans and other yeast species
Mishra, N., Prasad, T., Sharma, N., Payasi, A., Prasad, R., Gupta, D., & Singh, R. (2007) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/amicr.54.2007.3.1 · Cited by 168
“glabrata was much more frequent in patients with haematological malignancies than in those with solid tumors [146].”
Ullmann, A. J., Cornely, O. A., DonneNy, J. P., Akova, M., Arendrup, M. C., Arıkan-Akdağlı, S., Bassetti, M., Billé, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12037 · Cited by 164
Self-citationTortorano, A. M., Dho, G., Prigitano, A., Breda, G., Grancini, A., Emmi, V., Cavanna, C., Marino, G., Morero, S., Ossi, C. M., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02044.x · Cited by 164
Nucci, M., & Colombo, A. L. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.11.009 · Cited by 164
Candida tropicalisin human disease
Chai, L. Y. A., Denning, D. W., & Warn, P. A. (2010) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2010.489506 · Cited by 163
“C. tropicalis represents 3–66% of all Candida bloodstream isolates worldwide (Viscoli et al. 1999; Pfaller et al. 2000; Sipsas et al. 2009; Yap et al. 2009; Yang et al. 2009; Sabino et al. 2009; Tan et al. 2009) and in many centers is the second most common Candida isolated.”
BackgroundInfluentialColombo, A. L., Guimarães, T., Silva, L. R. B. F., Monfardini, L. P. D. A., Cunha, A. K. B., Rady, P., Alves, T., & Rosas, R. C. (2007) · Infection Control & Hospital Epidemiology · doi:10.1086/513615 · Cited by 162
Fungal Infections in Children With Cancer: A Prospective, Multicenter Surveillance Study
Castagnola, E., Cesaro, S., Giacchino, M., Livadiotti, S., Tucci, F., Zanazzo, G. A., Caselli, D., Caviglia, I., Parodi, S., Rondelli, R., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000220256.69385.2e · Cited by 161
Self-citationSystemic candidiasis in intensive care units: A multicenter, matched-cohort study
Leleu, G., Aegerter, P., & Guidet, B. (2002) · Journal of Critical Care · doi:10.1053/jcrc.2002.35815 · Cited by 160
Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia
Plantinga, T. S., Johnson, M. D., Scott, W. K., van de Vosse, E., Edwards, D. R. V., Smith, P. B., Alexander, B. D., Yang, J. C., Kremer, D., Laird, G. M., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir867 · Cited by 160
“antibiotics, prolonged ICU stay, and central venous catheterization [3–5].”
BackgroundRosen, G. P., Nielsen, K., Glenn, S., Abelson, J., Deville, J., & Moore, T. B. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000155861.38641.ca · Cited by 158
“Many prior studies have ascribed a shift toward non-albicans infections to widespread fluconazole prophylaxis.(3,30,31) There was no significant shift in the incidence of Candida species at this institution, possibly because antifungal prophylaxis was previously not used on a routine basis at our institution in this p…”
ResultDiagnosis of invasive candidiasis in the ICU
Eggimann, P., Billé, J., & Marchetti, O. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-37 · Cited by 158
“These observations are not only of epidemiological interest, but the decreased in vitro antifungal susceptibility has been showed to be associated with increased morbidity and mortality in both immunocompromised and critically ill patients [7,20].”
BackgroundAlam, F. F., Mustafa, A. S., & Khan, Z. U. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-103 · Cited by 154
“Background Candidemia is a major infectious and steadily increasing complication of seriously immunocompromised patients that is associated with high mortality rates [1-5].”
BackgroundCornely, O. A., Gachot, B., Akan, H., Bassetti, M., Uzun, Ö., Kibbler, C. C., Marchetti, O., de Burghgraeve, P., Ramadan, S., Pylkkänen, L., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ293 · Cited by 154
“In both studies non-albicans Candida species were more frequent in hematological disease than with solid tumors [5].”
BackgroundMethodResultInfluentialCytokines and fungal infections
Antachopoulos, C., & Roilides, E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05498.x · Cited by 154
Creaven, B. S., Egan, D. A., Kavanagh, K. A., McCann, M., Noble, A., Thati, B., & Walsh, M. (2006) · Inorganica Chimica Acta · doi:10.1016/j.ica.2006.04.006 · Cited by 152
Pagano, L., Busca, A., Candoni, A., Cattaneo, C., Cesaro, S., Fanci, R., Nadali, G., Potenza, L., Russo, D., Tumbarello, M., et al. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.09.002 · Cited by 148
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 148
Ruhnke, M., Böhme, A., Buchheidt, D., Cornely, O. A., Donhuijsen, K., Einsele, H., Enzensberger, R., Hebart, H. F., Heußel, C. P., Horger, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr407 · Cited by 142
“glabrata or Candida krusei in patients with granulocytopenia [31–33].”
BackgroundBöhme, A., Ruhnke, M., Buchheidt, D., Cornely, O. A., Einsele, H., Enzensberger, R., Hebart, H. F., Heinz, W., Junghanß, C., Karthaus, M., et al. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0622-5 · Cited by 141
“Additionally, the incidence of invasive Candida infections with primary fluconazole resistance like Candida krusei or reduced susceptibility like Candida glabrata is rising in hematological patients [30, 110]; therefore, an echinocandin should be preferred, even if mainly proven in nonneutropenic patients (AI).”
BackgroundColombo, A. L., Perfect, J. R., DiNubile, M. J., Bartizal, K. F., Motyl, M. R., Hicks, P. S., Lupinacci, R. J., Sable, C. A., & Kartsonis, N. A. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0973-8 · Cited by 141
“Risk factors, susceptibility patterns, and outcomes may differ by species and geographical region [14, 20, 21, 22, 23, 24, 25, 26, 27 ].”
BackgroundCandidemia in Finland, 1995–1999
Poikonen, E., Lyytikäinen, O., Anttila, V., & Ruutu, P. (2003) · Emerging infectious diseases · doi:10.3201/eid0908.030069 · Cited by 141
“The contribution of HIV infection as a predisposing risk factor for candidemia is further emphasized by a report from Italy, where Candida spp. was the third most common cause of nosocomial BSI in HIV patients (37).”
ResultInfluentialThe risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos‐Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 140
“It is possible that the observation by others [41] that patients infected by C.”
BackgroundAntoniadou, A., Torres, H. A., Lewis, R. E., Thornby, J. A., Bodey, G. P., Tarrand, J. P., Han, X.-Y., Rolston, K. V. I., Safdar, A., RAAD, I. I., et al. (2003) · Medicine · doi:10.1097/01.md.0000091182.93122.8e · Cited by 140
Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia
Uzun, O., Ascioglu, S., Anaissie, E. J., & Rex, J. H. (2001) · Clinical Infectious Diseases · doi:10.1086/320757 · Cited by 138
The global epidemiology of invasive Candida infections—is the tide turning?
Hobson, R. P. (2003) · Journal of Hospital Infection · doi:10.1016/j.jhin.2003.08.012 · Cited by 137
Genetic susceptibility to Candida infections
Smeekens, S. P., van de Veerdonk, F. L., Kullberg, B. J., & Netea, M. G. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201678 · Cited by 136
“Inflammasome and Th17 activation is considered to be a central event for the discrimination of colonization versus invasion with C. albicans at the level of the mucosa (Gow et al, 2011).”
Denture Stomatitis: Causes, Cures and Prevention
Hannah, V., O’Donnell, L. E., Robertson, D. P., & Ramage, G. (2017) · Primary Dental Journal · doi:10.1308/205016817822230175 · Cited by 136
Voriconazole Salvage Treatment of Invasive Candidiasis
Ostrosky-Zeichner, L. L., Lashof, A. M. L. O., Kullberg, B. J., & Rex, J. H. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-1014-3 · Cited by 134
“Hosts at risk include cancer patients (with and without neutropenia), transplant recipients, AIDS patients, critically ill patients, patients who undergo abdominal surgery, patients on parenteral nutrition, and premature infants [6, 7, 13, 14, 15].”
Background
Metadata
- Authors
- Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., De Pauw, B., Meunier, F., & the Invasive Fungal Infection Group of the EORTC
- Affiliations
- University of Genoa (IT)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-05
- Volume
- 28
- Issue
- 5
- Pages
- 1071-1079
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2126536749
- Cited by
- 601
- References
- 29
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 11 · 2022: 6 · 2021: 9 · 2020: 9 · 2019: 8 · 2018: 16 · 2017: 15 · 2016: 16 · 2015: 22 · 2014: 27 · 2013: 31 · 2012: 25
- FWCI
- 21.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, invasive fungal infections, cancer patients, Candida albicans, non-albicans Candida, Candida glabrata, solid tumors, hematologic malignancies, acute leukemia, neutropenia, antifungal prophylaxis, allogeneic bone marrow transplantation, septic shock, 30-day mortality, risk factors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Candida albicans, Candidiasis, Child, Child, Preschool, Cross Infection, Female, Humans, Male, Middle Aged, Neoplasms, Neutropenia, Population Surveillance, Prospective Studies, Multivariate Analysis, Survival Analysis, Hematologic Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.